Filing Analysis
Eledon Pharmaceuticals, Inc. filed an 8-K to announce the issuance of a press release regarding its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- The report covers the quarterly period ending June 30, 2026.
- A press release was issued on August 13, 2026, as Exhibit 99.1.
Eledon Pharmaceuticals reported the results of its Annual Meeting of Stockholders held on June 18, 2026. The meeting included the election of three Class III Directors, approval to increase authorized shares, and ratification of Deloitte & Touche LLP as independent auditors.
🚩 Red Flags
- Significant increase in authorized share count (from 300M to 450M) provides management with more flexibility for potential future equity dilution via secondary offerings or warrants.
📋 Key Facts
- Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares (Proposal 2).
- David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson were elected as Class III Directors for terms ending in 2029.
- Stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026.
- The increase in authorized shares was filed with the Secretary of State of Delaware on June 22, 2026.
Eledon Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued and the 8-K was filed on May 13, 2026.
- The document was signed by CEO David-Alexandre C. Gros, M.D.
Eledon Pharmaceuticals, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release on March 19, 2026.
📋 Key Facts
- The company reported financial results for the quarter and year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was issued on March 19, 2026, and is attached as Exhibit 99.1.
Eledon Pharmaceuticals entered into an exchange agreement with Coastlands Capital Partners LP on December 30, 2025. The transaction involves exchanging 4,203,764 shares of common stock for a pre-funded warrant to purchase an equivalent number of shares.
🚩 Red Flags
- Significant dilution risk: The exchange involves over 4.2 million shares, which represents a substantial portion of equity for a micro-cap company.
- Pre-funded warrant structure: Often used as an alternative to direct equity issuance, effectively delaying the impact on share count but creating immediate potential dilution.
📋 Key Facts
- Date of event: December 30, 2025
- Counterparty: Coastlands Capital Partners LP (the 'Holder')
- Common Stock exchanged: 4,203,764 shares
- Warrant type: Pre-funded warrant to purchase up to 4,203,764 shares of Common Stock
- Exercise price: $0.001 per share (subject to adjustments)
- Beneficial ownership limitation: Initially capped at 4.99%, with potential increase to 19.99% upon 61 days' notice
- Exemption used: Section 3(a)(9) of the Securities Act
Eledon Pharmaceuticals, Inc. filed an 8-K to announce the issuance of a press release regarding its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing relates to Item 2.02 (Results of Operations and Financial Condition).
- The report covers the quarterly period ending September 30, 2025.
- A press release was issued on November 14, 2025, as Exhibit 99.1.
Eledon Pharmaceuticals entered into an underwriting agreement to conduct a public offering of common stock and pre-funded warrants. The offering aims to raise approximately $46.5 million to fund clinical development and general corporate purposes.
🚩 Red Flags
- Significant dilution likely due to the issuance of over 15 million shares and a nearly identical number of pre-funded warrants.
- The use of 'pre-funded warrants' is often used when companies cannot issue common stock directly without triggering certain regulatory or ownership thresholds, frequently seen in distressed or highly dilutive financing rounds.
📋 Key Facts
- Offering size: 15,152,485 shares of Common Stock at $1.65 per share.
- Pre-funded warrants: 15,151,515 warrants priced at $1.649 per warrant (exercisable at $0.001 per share).
- Underwriter option: Underwriters have an option to purchase up to 4,545,600 additional shares.
- Estimated net proceeds: Approximately $46.5 million (potentially increasing to $53.6 million if the option is fully exercised).
- Lock-up period: Executive officers and directors are subject to a 60-day lock-up agreement from November 12, 2025.
- Expected closing date: On or about November 13, 2025.
Eledon Pharmaceuticals announced preliminary cash and cash equivalents of approximately $93.4 million as of September 30, 2025, and released Phase 2 BESTOW clinical trial results for tegoprubart.
🚩 Red Flags
- Financial figures provided are unaudited and preliminary estimates only.
📋 Key Facts
- Estimated cash, cash equivalents, and short-term investments: ~$93.4 million (as of Sept 30, 2025).
- The financial data is unaudited, preliminary, and subject to management review.
- Announced results from the Phase 2 BESTOW trial evaluating tegoprubart for preventing organ rejection in de novo kidney transplant patients.
- Scheduled a conference call for November 7, 2025, to discuss clinical data.
Eledon Pharmaceuticals has announced that previously issued financial statements for fiscal years 2023 and 2024, as well as several quarterly reports in 2024 and 2025, can no longer be relied upon due to errors in the classification of Series X non-voting convertible preferred stock. The company identified a material weakness in its internal control over financial reporting related to accounting for equity instruments.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02)
- Material weakness in internal control over financial reporting
- Reclassification of permanent equity to temporary equity, which can impact certain debt-to-equity ratios and financial covenants
📋 Key Facts
- The error involves the misclassification of Series X and Series X1 non-voting convertible preferred stock, which should have been classified as temporary equity rather than permanent equity under ASC 480.
- Impacted reports include the 2024 Form 10-K, the 2025 Form 10-Q, and several quarterly reports from 2024 and early 2025.
- The company identified a material weakness in internal control over financial reporting related to equity instrument accounting.
- Management stated that errors did not impact cash, short-term investment position, liquidity, or results of operations.
- Restatements will be required for the consolidated balance sheets and statements of stockholders' equity.
Eledon Pharmaceuticals issued an 8-K to announce the release of updated Phase 1b clinical trial data for tegoprubart, presented at the World Transplant Congress. The company is also hosting a conference call to discuss these results.
📋 Key Facts
- Announced updated Phase 1b open-label trial data for tegoprubart.
- The study evaluates tegoprubart for preventing organ rejection in kidney transplant patients.
- Data was presented at the World Transplant Congress in San Francisco, CA on August 6, 2025.
- Company is hosting a conference call to discuss clinical data results.
Eledon Pharmaceuticals held its Annual Meeting of Stockholders on June 10, 2025, where shareholders approved several key corporate governance and structural changes. These include increasing authorized shares and extending officer exculpation protections.
🚩 Red Flags
- The increase in authorized shares (from 200M to 300M) provides the company with more capacity for potential future equity dilution via new share issuances.
📋 Key Facts
- Stockholders increased authorized common stock from 200,000,000 to 300,000,000 shares (Proposal 2).
- Stockholders approved an amendment to provide exculpation for certain officers (Proposal 3).
- Three Class II Directors (Keith A. Katkin, Allan D. Kirk, and John S. McBride) were elected for terms ending in 2028.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Eledon Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Includes Exhibit 99.1 containing the press release for financial results
Eledon Pharmaceuticals, Inc. filed an amendment to its 8-K to correct a clerical error regarding the tenure of its former auditor and to confirm the dismissal of Crowe LLP and the appointment of Deloitte & Touche LLP as its new independent registered public accounting firm.
🚩 Red Flags
- Auditor change (Crowe LLP dismissed after less than one year of service).
- Amendment filed to correct previous errors in reporting auditor tenure/matters.
📋 Key Facts
- Dismissal of Crowe LLP effective April 1, 2025.
- Appointment of Deloitte & Touche LLP for fiscal year ending December 31, 2025, and related interim periods.
- Crowe LLP served from July 10, 2024, to April 1, 2025.
- The Company stated there were no disagreements with Crowe regarding accounting principles, practices, or auditing scope/procedures.
- The audit report for the fiscal year ended December 31, 2024, was not adverse, qualified, or modified.
Eledon Pharmaceuticals, Inc. has dismissed its independent registered public accounting firm, Crowe LLP, and appointed Deloitte & Touche LLP as its new auditor for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change (though no disagreement was reported, this is a standard red flag in micro-cap analysis to monitor for potential undisclosed issues).
📋 Key Facts
- Dismissal of Crowe LLP effective April 1, 2025.
- Appointment of Deloitte & Touche LLP effective April 1, 2025.
- The company stated there were no disagreements with Crowe regarding accounting principles, practices, or auditing scope during the two most recent fiscal years (2023 and 2024) or the interim period in 2025.
- Audit reports for FY2023 and FY2024 did not contain adverse opinions, disclaimers of opinion, or qualifications.
Eledon Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 20, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were released via press release attached as Exhibit 99.1
Eledon Pharmaceuticals amended its CEO's employment agreement to adjust the market value caps associated with his performance-based bonus structure. The amendment establishes a sliding scale for bonuses based on company market capitalization reaching between $600 million and $1.5 billion.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Date of Agreement: December 16, 2024
- CEO David-Alexandre Gros's employment agreement was amended to modify the Performance Bonus market value cap.
- Bonus threshold starts at a $6 million payment if Company market value exceeds $600 million.
- Maximum bonus of $15 million is payable if Company market value reaches $1.5 billion, using linear interpolation.
Eledon Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
📋 Key Facts
- The filing was made on November 12, 2024.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- Financial results are for the quarter ended September 30, 2024.
- A press release containing the results was issued as Exhibit 99.1.
Eledon Pharmaceuticals announced a significant underwritten public offering of common stock and pre-funded warrants to raise approximately $79.5 million in net proceeds. The offering is intended to fund the company's clinical pipeline, working capital, and general corporate purposes.
🚩 Red Flags
- Significant dilution: The issuance of over 18 million shares and nearly 5 million warrant-equivalent shares will result in substantial dilution for existing shareholders.
- Warrant structure: Use of pre-funded warrants is a common mechanism in micro-cap financing to circumvent certain regulatory or ownership thresholds, often signaling high demand from institutional investors but potentially complicating the cap table.
📋 Key Facts
- Offering size: 18,356,173 shares of common stock at $3.65 per share.
- Pre-funded warrants: Issued at $3.649 per warrant, exercisable for 4,931,507 shares at $0.001 per share.
- Estimated net proceeds: Approximately $79.5 million after discounts and expenses.
- Underwriter: Leerink Partners, LLC acting as representative for several underwriters.
- Lock-up period: 90 days from October 29, 2024, for company executive officers and directors.
- Beneficial ownership limit: Holders of pre-funded warrants are subject to a 4.99% (or 9.99%) ownership cap unless otherwise specified.
Eledon Pharmaceuticals issued a press release regarding initial clinical data for tegoprubart in type 1 diabetes subjects following islet transplantation. The company also updated its investor presentation.
📋 Key Facts
- Announced initial data from an investigator-initiated trial at the University of Chicago Medicine’s Transplantation Institute.
- The study involves subjects with type 1 diabetes treated with tegoprubart (investigational anti-CD40L antibody) as part of an immunosuppression regimen following islet transplantation.
- Updated investor presentation was released on October 29, 2024.
Eledon Pharmaceuticals completed two tranches of common stock sales on September 30 and October 1, 2024, as part of an existing Securities Purchase Agreement. The transactions resulted in approximately $4.0 million in gross proceeds.
🚩 Red Flags
- Dilution: The issuance of 1.7 million+ new shares will dilute existing shareholders.
- Continued reliance on private placements/equity sales to fund operations (typical for clinical-stage biotech).
📋 Key Facts
- Completed sale of 1,527,400 shares on September 30, 2024.
- Completed sale of 200,000 shares on October 1, 2024.
- Total gross proceeds from these sales: approximately $4.0 million.
- Sales were conducted pursuant to a Securities Purchase Agreement dated April 28, 2023.
- Shares were sold under Section 4(a)(2) and Rule 506(b) exemptions.
Eledon Pharmaceuticals entered into an Open Market Sale Agreement with Guggenheim Securities to execute an 'at the market' (ATM) equity offering. The program allows for the sale of common stock with aggregate proceeds of up to $75,000,000.
🚩 Red Flags
- Potential for immediate share dilution as the company can sell shares 'from time to time'.
- ATM offerings are often used by micro-cap biotech companies to fund ongoing clinical trials/burn rates, which can create downward pressure on stock price during sales periods.
📋 Key Facts
- Entered into Sales Agreement with Guggenheim Securities, LLC on September 20, 2024.
- Aggregate sales proceeds target: up to $75,000,000.
- Offering type: 'At the market' (ATM) equity offering under Rule 415(a)(4).
- Guggenheim Securities compensation is 3.0% of gross proceeds.
- Shares will be issued pursuant to a shelf registration statement on Form S-3 filed on September 20, 2024 (File No. 333-282260).
- The Company maintains control over sale parameters, including timing and minimum price.
Eledon Pharmaceuticals is restating multiple prior financial reports due to the misclassification of certain warrants as equity rather than liability instruments. This follows an auditor change and the identification of a material weakness in internal controls over financial reporting.
🚩 Red Flags
- Auditor change combined with restatement (Red Flag Escalator)
- Material weakness in internal control over financial reporting
- Non-reliance on previously issued audited and unaudited financial statements
- Restatement of multiple historical periods (FY 2023 and several quarters in 2023/2024)
📋 Key Facts
- The company dismissed KMJ Corbin & Company LLP on July 10, 2024, and appointed Crowe LLP as its new independent auditor.
- Warrants issued in May 2023 (Common Warrants) and Subsequent Closing Warrants were incorrectly classified as equity; they must be recorded as liabilities under ASC 815-40.
- Impacted reports include the FY 2023 10-K, Q1 2024 10-Q, and several 10-Qs from 2023.
- The company identified a material weakness in internal control over financial reporting related to accounting for equity instruments.
- Management states the errors are non-cash and do not impact cash runway or operations.
Eledon Pharmaceuticals has dismissed its independent auditor, KMJ Corbin & Company LLP, and appointed Crowe LLP following the merger of KMJ's professional staff into Crowe. While no disagreements were reported, previous audit reports contained going concern language.
🚩 Red Flags
- Going concern language in the two most recently completed fiscal years (2022 and 2023).
- Auditor change triggered by the predecessor firm's staff joining another firm, which can sometimes complicate transition/onboarding.
📋 Key Facts
- KMJ Corbin & Company LLP was dismissed as the independent registered public accounting firm on July 10, 2024.
- Crowe LLP was appointed as the new independent registered public accounting firm on July 10, 2024.
- The dismissal follows KMJ's professional staff joining Crowe LLP on May 20, 2024.
- Audit reports for fiscal years ended December 31, 2023, and 2022 contained an explanatory paragraph regarding the Company's ability to continue as a going concern.
Eledon Pharmaceuticals completed a second closing of a previously contemplated equity sale on July 8, 2024. The transaction involved the issuance of common stock to institutional and accredited investors.
🚩 Red Flags
- Dilutive event: Issuance of nearly 1 million new shares of common stock.
📋 Key Facts
- Completed sale of 909,088 shares of common stock ($0.001 par value).
- Gross proceeds generated: approximately $2.1 million.
- Transaction was part of a Securities Purchase Agreement dated April 28, 2023.
- Shares were sold under Section 4(a)(2) and Rule 506(b) exemptions.
Eledon Pharmaceuticals held its Annual Meeting of Stockholders on July 10, 2024, resulting in the election of two new directors and the approval of an amendment to the 2020 Long Term Incentive Plan. The meeting also included the ratification of the company's independent auditor and several board committee reassignments following a director retirement.
📋 Key Facts
- Stockholders approved increasing the aggregate share limit of the 2020 Incentive Plan by 3,500,000 shares (new total: 17,960,000 shares).
- Dr. Steven Perrin and Dr. June Lee were elected as Class I Directors for terms ending in 2027.
- KMJ Corbin & Company LLP was ratified as the independent registered public accounting firm for FY2024.
- Walter Ogier retired from the Board of Directors, vacating seats on the Audit and Compensation Committees.
- Dr. Allan Kirk joined the Audit Committee; Mr. John McBride joined the Compensation Committee; Dr. Jan Hillson joined the Nominating and Corporate Governance Committee.
Eledon Pharmaceuticals, Inc. filed an 8-K to announce the issuance of its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were announced via press release on May 9, 2024.
- Reporting period covered: Quarter ended March 31, 2024.
Eledon Pharmaceuticals entered into a $50 million private placement agreement to issue common stock and pre-funded warrants to institutional investors. The proceeds are intended for product pre-commercial activities and general corporate purposes.
🚩 Red Flags
- Significant potential dilution due to the issuance of over 13 million shares and nearly 8 million warrant-linked shares.
- Pre-funded warrants act as a delayed equity issuance, effectively diluting existing shareholders upon exercise (which is immediate).
- Registration Rights Agreement includes cash penalties for failure to meet filing/effectiveness timelines.
📋 Key Facts
- Total gross proceeds expected: approximately $50 million.
- Issuance of 13,110,484 shares of common stock at $2.37 per share.
- Issuance of pre-funded warrants for 7,989,516 shares at a price of $2.369 per underlying share.
- Warrants are exercisable immediately at an exercise price of $0.001 per share.
- Registration Rights Agreement requires filing an S-3 registration statement within 20 days to register the shares for resale.
- Leerink Partners acting as lead placement agent; LifeSci Capital and Noble Capital Markets as co-placement agents.
Eledon Pharmaceuticals, Inc. filed an 8-K to announce its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal mechanism to provide the press release containing these results.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Quarter and year ended December 31, 2023
- The filing is made pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Included Exhibit 99.1 contains the full press release regarding financial results